logo
Plus   Neg
Share
Email

AstraZeneca: Lynparza Receives Positive CHMP Opinion For Expanded Indication

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending Lynparza (olaparib) as a 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer, AstraZeneca plc (AZN.L,AZN) stated. Lynparza is currently approved in 64 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status.

Lynparza, which is being jointly developed by AstraZeneca and MSD or Merck & Co., Inc., is approved for advanced ovarian cancer and metastatic breast cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The German government has approved a 9 billion euros rescue package for Deutsche Lufthansa AG (DLAKF, DLAKY), which is the largest German corporate rescue package since the coronavirus crisis struck. The airline has also agreed to the rescue deal. JetBlue Airways said it will continue to block middle seats in rows where passengers are not traveling together through the July 4 holiday. JetBue will block middle seats on its Airbus aircraft, while it will block aisle seats on its smaller Embraer 190 aircraft. Customers traveling together will be allowed to sit in the middle and aisle seats. The U.S. Food and Drug Administration or FDA announced on its website that New Hoque and Sons, Inc. is recalling Radhuni Curry Powder distributed in New York City, New York due to potential Salmonella contamination. The recall was made after it was found that the finished products contained several strains of Salmonella, the company said.
Follow RTT